GlassScriptPhysician profile
Helen Tergin
NPI 1578540571
$6,462.88
in general payments reported to CMS, 2019-2025
27 companies · $666 in 2025
The $666 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $482 · 2021: $1,064 · 2022: $1,017 · 2023: $1,270 · 2024: $885 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.83 |
| Education | $192.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,189.02 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $941.95 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $727.83 | 2019-2025 | |
| Merz North America, INC. | $654.36 | 2019-2023 | Xeomin |
| Pfizer INC. | $390.58 | 2019-2024 | |
| Lilly USA, LLC | $281.99 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Allergan, INC. | $255.01 | 2019-2022 | |
| Ucb, INC. | $218.46 | 2019-2024 | Cimzia |
| Amgen INC. | $110.09 | 2021-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $105.58 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $93.79 | 2022-2023 | Sotyktu |
| Galderma Laboratories, L.P. | $83.42 | 2019-2022 | |
| Leo Pharma INC. | $50.16 | 2019 | |
| Aclaris Therapeutics, INC. | $49.29 | 2019 | |
| Dusa Pharmaceuticals, INC. | $44.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $38.76 | 2021-2022 | |
| Prugen, INC. Pharmaceuticals | $35.34 | 2019-2020 | |
| Biofrontera INC. | $31.70 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $29.90 | 2020-2021 | |
| Genentech USA, INC. | $26.48 | 2019 | |
| Krystal Biotech INC | $22.68 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.70 | 2023 | Cyltezo |
| Convatec INC. | $15.22 | 2024 | |
| Epi Health, LLC | $13.90 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.43 | 2019 | |
| Dermira, INC. | $12.05 | 2019 | |
| Celgene Corporation | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Tergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.